-
Abbink P, Maxfield LF, Ng'ang'a D, Borducchi EN, Iampietro MJ, Bricault CA, Teigler JE, Blackmore S, Parenteau L, Wagh K, Handley SA, Zhao G, Virgin HW, Korber B, Barouch DH (2015) Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J Virol 89: 1512-1522
doi: 10.1128/JVI.02950-14
-
Amanat F, Krammer F (2020) Sars-cov-2 vaccines: status report. Immunity 52: 583-589
doi: 10.1016/j.immuni.2020.03.007
-
Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC, Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd J-PM, Pessaint L, Van Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell T-A, Cook A, Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng IT, Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-Jones G, Himansu S, Kong W-P, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, Gaudinski MR, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M, Seder RA, Graham BS (2020) Evaluation of the mrna-1273 vaccine against sars-cov-2 in nonhuman primates. N Engl J Med 383: 1544-1555
doi: 10.1056/NEJMoa2024671
-
Dorozhkin SV (2013) A detailed history of calcium orthophosphates from 1770s till 1950. Mater Sci Eng C Mater Biol Appl 33: 3085-3110
doi: 10.1016/j.msec.2013.04.002
-
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ (2020) Safety and immunogenicity of the chadox1 ncov-19 vaccine against sars-cov-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396: 467-478
doi: 10.1016/S0140-6736(20)31604-4
-
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C (2020) Development of an inactivated vaccine candidate for sars-cov-2. Science 369: 77-81
doi: 10.1126/science.abc1932
-
Graham SP, McLean RK, Spencer AJ, Belij-Rammerstorfer S, Wright D, Ulaszewska M, Edwards JC, Hayes JWP, Martini V, Thakur N, Conceicao C, Dietrich I, Shelton H, Waters R, Ludi A, Wilsden G, Browning C, Bialy D, Bhat S, Stevenson-Leggett P, Hollinghurst P, Gilbride C, Pulido D, Moffat K, Sharpe H, Allen E, Mioulet V, Chiu C, Newman J, Asfor AS, Burman A, Crossley S, Huo JD, Owens RJ, Carroll M, Hammond JA, Tchilian E, Bailey D, Charleston B, Gilbert SC, Tuthill TJ, Lambe T (2020) Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored covid-19 vaccine candidate chadox1 ncov-19. NPJ Vaccines 5: 69
doi: 10.1038/s41541-020-00221-3
-
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH, m RNASG (2020) An mrna vaccine against sars-cov-2 - preliminary report. N Engl J Med 383: 1920-1931
doi: 10.1056/NEJMoa2022483
-
Jiang D, Premachandra GS, Johnston C, Hem SL (2004) Structure and adsorption properties of commercial calcium phosphate adjuvant. Vaccine 23: 693-698
doi: 10.1016/j.vaccine.2004.06.029
-
Lin Y, Wang X, Huang X, Zhang J, Xia N, Zhao Q (2017) Calcium phosphate nanoparticles as a new generation vaccine adjuvant. Expert Rev Vaccines 16: 895-906
doi: 10.1080/14760584.2017.1355733
-
Lin J, Wang X, Tang R (2019) Regulations of organism by materials: a new understanding of biological inorganic chemistry. J Biol Inorg Chem 24: 467-482
doi: 10.1007/s00775-019-01673-2
-
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (2020) Safety and immunogenicity of an rad26 and rad5 vector-based heterologous prime-boost covid-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396: 887-897
doi: 10.1016/S0140-6736(20)31866-3
-
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565-574
doi: 10.1016/S0140-6736(20)30251-8
-
Luo S, Zhang P, Ma X, Wang Q, Lu J, Liu B, Zhao W, Allain JP, Li C, Li T (2019) A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development. Virus Res 268: 1-10
doi: 10.1016/j.virusres.2019.05.008
-
Luo S, Zhang P, Liu B, Yang C, Liang C, Wang Q, Zhang L, Tang X, Li J, Hou S, Zeng J, Fu Y, Allain J-P, Li T, Zhang Y, Li C (2021) Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored covid-19 vaccine candidates. Emerg Microbes Infect 10: 1002-1015
doi: 10.1080/22221751.2021.1931466
-
Luo S, Zhao W, Ma X, Zhang P, Liu B, Zhang L, Wang W, Wang Y, Fu Y, Allain J-P, Li T, Li C (2020) A high infectious simian adenovirus type 23 vector based vaccine efficiently protects common marmosets against zika virus infection. Plos Negl Trop Dis 14: e0008027
doi: 10.1371/journal.pntd.0008027
-
Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, He X, Martinez DR, Rutten L, Bos R, van Manen D, Vellinga J, Custers J, Langedijk JP, Kwaks T, Bakkers MJG, Zuijdgeest D, Huber SKR, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Hoffman E, Jacob-Dolan C, Kirilova M, Li Z, Lin Z, Mahrokhian SH, Maxfield LF, Nampanya F, Nityanandam R, Nkolola JP, Patel S, Ventura JD, Verrington K, Wan H, Pessaint L, Ry AV, Blade K, Strasbaugh A, Cabus M, Brown R, Cook A, Zouantchangadou S, Teow E, Andersen H, Lewis MG, Cai Y, Chen B, Schmidt AG, Reeves RK, Baric RS, Lauffenburger DA, Alter G, Stoffels P, Mammen M, Hoof JV, Schuitemaker H, Barouch DH (2020) Single-shot ad26 vaccine protects against sars-cov-2 in rhesus macaques. Nature 586: 583-588
doi: 10.1038/s41586-020-2607-z
-
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi P-Y, Tureci O, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Sahin U, Jansen KU (2020) Phase 1/2 study of covid-19 rna vaccine bnt162b1 in adults. Nature 586: 589-593
doi: 10.1038/s41586-020-2639-4
-
Shen H, Tan J, Saltzman WM (2004) Surface-mediated gene transfer from nanocomposites of controlled texture. Nat Mater 3: 569-574
doi: 10.1038/nmat1179
-
Srinivasan S, Cui H, Gao Z, Liu M, Lu S, Mkandawire W, Narykov O, Sun M, Korkin D (2020) Structural genomics of sars-cov-2 indicates evolutionary conserved functional regions of viral proteins. Viruses 12: 360
doi: 10.3390/v12040360
-
Tostanoski LH, Wegmann F, Martinot AJ, Loos C, McMahan K, Mercado NB, Yu J, Chan CN, Bondoc S, Starke CE, Nekorchuk M, Busman-Sahay K, Piedra-Mora C, Wrijil LM, Ducat S, Custers J, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS (2020) Ad26 vaccine protects against sars-cov-2 severe clinical disease in hamsters. Nat Med 26: 1694-1700
doi: 10.1038/s41591-020-1070-6
-
van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, Feldmann F, Allen ER, Sharpe H, Schulz J, Holbrook M, Okumura A, Meade-White K, Pérez-Pérez L, Edwards NJ, Wright D, Bissett C, Gilbride C, Williamson BN, Rosenke R, Long D, Ishwarbhai A, Kailath R, Rose L, Morris S, Powers C, Lovaglio J, Hanley PW, Scott D, Saturday G, de Wit E, Gilbert SC, Munster VJ (2020) ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586: 578-582
doi: 10.1038/s41586-020-2608-y
-
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the sars-cov-2 spike glycoprotein. Cell 181: 281-292
doi: 10.1016/j.cell.2020.02.058
-
Walters R, Welsh M (1999) Mechanism by which calcium phosphate coprecipitation enhances adenovirus-mediated gene transfer. Gene Ther 6: 1845-1850
doi: 10.1038/sj.gt.3301020
-
Wang X, Deng Y, Li S, Wang G, Qin E, Xu X, Tang R, Qin C (2012) Biomineralization-based virus shell-engineering: Towards neutralization escape and tropism expansion. Adv Healthc Mater 1: 443-449
doi: 10.1002/adhm.201200034
-
Wang G, Cao RY, Chen R, Mo L, Han JF, Wang X, Xu X, Jiang T, Deng YQ, Lyu K, Zhu SY, Qin ED, Tang R, Qin CF (2013) Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions. Proc Natl Acad Sci U S A 110: 7619-7624
doi: 10.1073/pnas.1300233110
-
Wang X, Sun C, Li P, Wu T, Zhou H, Yang D, Liu Y, Ma X, Song Z, Nian Q, Feng L, Qin C, Chen L, Tang R (2016) Vaccine engineering with dual-functional mineral shell: a promising strategy to overcome preexisting immunity. Adv Mater 28: 694-700
doi: 10.1002/adma.201503740
-
Wang Q, Sun Y, Xu Y, Wang Y, Wang H, Fu Y, Allain JP, Li C, Li T (2019) Seroprevalence of human adenovirus type 5 neutralizing antibody in common marmosets determined by a new set of two assays. Viral Immunol 32: 348-354
doi: 10.1089/vim.2019.0054
-
Wang C, Horby PW, Hayden FG, Gao GF (2020a) A novel coronavirus outbreak of global health concern. Lancet 395: 470-473
doi: 10.1016/S0140-6736(20)30185-9
-
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X (2020b) Development of an inactivated vaccine candidate, bbibp-corv, with potent protection against sars-cov-2. Cell 182: 713-721
doi: 10.1016/j.cell.2020.06.008
-
Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, Martinez DR, Loos C, Atyeo C, Fischinger S, Burke JS, Slein MD, Chen Y, Zuiani A, Lelis FJN, Travers M, Habibi S, Pessaint L (2020) DNA vaccine protection against sars-cov-2 in rhesus macaques. Science 369: 806-811
doi: 10.1126/science.abc6284
-
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W (2020a) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored covid-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395: 1845-1854
doi: 10.1016/S0140-6736(20)31208-3
-
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W (2020b) Immunogenicity and safety of a recombinant adenovirus type-5-vectored covid-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396: 479-488
doi: 10.1016/S0140-6736(20)31605-6